Atsuko Nakazawa
Overview
Explore the profile of Atsuko Nakazawa including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
167
Citations
880
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Asano T, Morimoto A, Nakazawa A, Ueda T, Ogawa C, Sakata N, et al.
Int J Hematol
. 2025 Mar;
PMID: 40063331
Background: Rosai-Dorfman-Destombes disease (RDD) is a rare form of histiocytosis, characterized by the accumulation of S100 protein-positive and CD1a-negative histiocytes with emperipolesis. Recently, oncogenic mutations in mitogen-activated protein kinase pathway...
2.
Inoue S, Ikai M, Nambu R, Moriya K, Kojima R, Tagami Y, et al.
Clin Immunol
. 2025 Mar;
274:110470.
PMID: 40037506
IKAROS, encoded by IKZF1, is a crucial transcription factor regulating hematopoiesis and B cell development. While IKZF1 haploinsufficiency variants are associated with various immunological disorders, inflammatory bowel disease (IBD) has...
3.
Sekimizu M, Watanabe T, Fukushima H, Koh K, Yuza Y, Takeshima Y, et al.
Pediatr Blood Cancer
. 2025 Feb;
:e31590.
PMID: 39948694
Background: Localized lymphoblastic lymphoma (LL) is rare in pediatric patients. The best treatment for patients with localized LL remains to be determined because of the rarity of the disease. Methods:...
4.
Fukuoka K, Zhao J, Oshima K, Honda M, Mitani Y, Mori M, et al.
Br J Haematol
. 2024 Oct;
205(6):2519-2522.
PMID: 39463037
No abstract available.
5.
Okada R, Takenobu H, Satoh S, Sugino R, Onuki R, Haruta M, et al.
Genes Cells
. 2024 Aug;
29(10):838-853.
PMID: 39189159
Epigenetic alterations critically affect tumor development. Polycomb-group complexes constitute an evolutionarily conserved epigenetic machinery that regulates stem cell fate and development. They are implicated in tumorigenesis, primarily via histone modification....
6.
Hosoi H, Miyachi M, Teramukai S, Sakabayashi S, Tsuchiya K, Kuwahara Y, et al.
Int J Clin Oncol
. 2024 Aug;
29(11):1746-1755.
PMID: 39177879
Background: Failure-free survival (FFS) rates of low-risk patients with rhabdomyosarcoma improved in Intergroup Rhabdomyosarcoma Study IV after the escalation of cyclophosphamide total dose to 26.4 g/m. However, this dose may...
7.
Ono R, Sakamoto K, Kudo K, Sato A, Kudo K, Fujino H, et al.
BMJ Open
. 2024 Jun;
14(6):e084159.
PMID: 38910000
Introduction: Although the prognosis of Langerhans cell histiocytosis (LCH) is excellent, the high recurrence rate and permanent consequences, such as central diabetes insipidus and LCH-associated neurodegenerative diseases, remain to be...
8.
Miyazaki N, Takami S, Uemura M, Oiki H, Takahashi M, Kawashima H, et al.
Commun Med (Lond)
. 2024 Jun;
4(1):111.
PMID: 38862768
Background: Biliary atresia (BA) is an intractable disease of unknown cause that develops in the neonatal period. It causes jaundice and liver damage due to the destruction of extrahepatic biliary...
9.
Yoneda A, Shichino H, Hishiki T, Matsumoto K, Ohira M, Kamijo T, et al.
Pediatr Blood Cancer
. 2024 Apr;
71(6):e30976.
PMID: 38577760
Purpose: Survival rates of patients with high-risk neuroblastoma are unacceptable. A time-intensified treatment strategy with delayed local treatment to control systemic diseases has been developed in Japan. We conducted a...
10.
Sekimizu M, Fukano R, Koga Y, Mitsui T, Fujita N, Mori T, et al.
BMJ Open
. 2024 Mar;
14(3):e080762.
PMID: 38508620
Introduction: Children and adolescents with mature B cell non-Hodgkin lymphoma (B-NHL) are treated with short-intensive chemotherapy. The burden of short-term and long-term toxicity is highly relative to its high cure...